Jaguar Health, Inc.

San Francisco, CA · Founded 2013 · CIK 0001585608 · Biotech · Private

Plant-based prescription medicines derived from natural botanical sources

jaguar.health →

Grants: —; No SBIR or STTR on record; Sector median: 1
Raised: $146M; 40 Form D · Nov 2025; 10 months since last filing
Contracts: —; No federal contracts on record
Patents: 10; 0 granted · 10 pending; Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount

Federal ↑Equity ↓

20122014201620182020202220242026

Capital and federal award history
Date	Event	Source	Amount
05 Sept 2013	Private capital raised	Form D · SEC	$200,000
10 Feb 2014	Private capital raised	Form D · SEC	$2,000,000
16 Jun 2014	Private capital raised	Form D · SEC	$300,000
12 Sept 2014	Private capital raised	Form D · SEC	$1,112,500
06 Mar 2015	Private capital raised	Form D · SEC	$1,000,000
09 Mar 2015	Private capital raised	Form D · SEC	$900,000
02 Apr 2015	Private capital raised	Form D · SEC	$1,000,000
30 Aug 2017	Private capital raised	Form D · SEC	$44,796,553
11 Jan 2018	Private capital raised	Form D · SEC	$801,100
30 Mar 2018	Private capital raised· 1 of 2 same day	Form D · SEC	$1,587,500
30 Mar 2018	Private capital raised· 2 of 2 same day	Form D · SEC	$2,155,000
02 Apr 2018	Private capital raised· 1 of 4 same day	Form D · SEC	$9,199,001
02 Apr 2018	Private capital raised· 2 of 4 same day	Form D · SEC	$1,090,340
02 Apr 2018	Private capital raised· 3 of 4 same day	Form D · SEC	$2,240,909
02 Apr 2018	Private capital raised· 4 of 4 same day	Form D · SEC	$4,999,999
24 Sept 2018	Private capital raised	Form D · SEC	$569,998
27 Sept 2018	Private capital raised	Form D · SEC	$774,844
03 Apr 2019	Private capital raised	Form D · SEC	$800,000
06 Jan 2020	Private capital raised	Form D · SEC	$1,500,000
07 Apr 2020	Private capital raised	Form D · SEC	$2,030,000
08 Apr 2020	Private capital raised	Form D · SEC	$720,000
05 Jun 2020	Private capital raised	Form D · SEC	$4,447,779
17 Sept 2020	Private capital raised	Form D · SEC	$1,087,500
04 Feb 2021	Private capital raised· 1 of 2 same day	Form D · SEC	$12,000,000
04 Feb 2021	Private capital raised· 2 of 2 same day	Form D · SEC	$6,220,812
26 Mar 2021	Private capital raised	Form D · SEC	$10,000,000
24 Sept 2021	Private capital raised	Form D · SEC	$776,197
25 Apr 2022	Private capital raised· 1 of 2 same day	Form D · SEC	$39,800
25 Apr 2022	Private capital raised· 2 of 2 same day	Form D · SEC	$7,572
26 Apr 2022	Private capital raised	Form D · SEC	$50,820
08 Jul 2022	Private capital raised	Form D · SEC	$300,000
02 Sept 2022	Private capital raised	Form D · SEC	$12,000,000
23 Sept 2022	Private capital raised	Form D · SEC	$7,140
11 May 2023	Private capital raised· 1 of 2 same day	Form D · SEC	$1,832,304
11 May 2023	Private capital raised· 2 of 2 same day	Form D · SEC	$1,857,453
30 Nov 2023	Private capital raised	Form D · SEC	$60,000
28 May 2025	Private capital raised	Form D · SEC	$1,500,003
23 Sept 2025	Private capital raised	Form D · SEC	$2,377,000
10 Oct 2025	Private capital raised	Form D · SEC	$1,000,000
24 Nov 2025	Private capital raised	Form D · SEC	$10,810,000

Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value

Biotech companies ranked by federal contract value
#	Company	Contracts	Disclosed equity
2378	XFIBRA, INC.	—	—
2379	ISIS PHARMACEUTICALS INC	—	$201M
2380	MANUS BIO INC	—	$109M
2381	Jaguar Health, Inc.	—	$146M
2382	MediWound Ltd.	—	$31M
2383	SALIX PHARMACEUTICALS LTD	—	$750M
2384	Stemsynergy Therapeutic	—	—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 28 related persons

Ari AzhirDirector
James BochnowskiDirector
Joseph BochnowskiDirector
Pravin ChaturvediExecutive Officer
Lisa ConteDirector · Executive Officer · Promoter
Greg DivasDirector
Greg DivisDirector
Anula JayasuriyaDirector
Jeffery JohnsonDirector
Jeffrey JohnsonDirector
John KallassyExecutive Officer
Folkert KamphuisDirector
Steven KingExecutive Officer
Carol LizakExecutive Officer
Carol LIzakExecutive Officer
Murray MacNaughtanDirector
Serge MartinodExecutive Officer
John Micek IIIDirector
John Micek, IIIDirector
Jiahao QuiDirector
Joe QuiDirector
Jonathan SiegelDirector
Charles ThompsonExecutive Officer
Charles ThomspnExecutive Officer
Jonathan WolinExecutive Officer
Jonathan WolingExecutive Officer
Karen WrightExecutive Officer
Zhi YangDirector

Patents

USPTO · 0 granted of 10

01 Feb 2018Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-Human Animalsapplication
25 Jan 2018Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animalsapplication
04 May 2017Methods of Treating Diarrhea in Adult Non-Human Animalsapplication
06 Apr 2017Methods of Treating Salmonella-Induced Diarrhea in Non-Human Animalsapplication
26 May 2016Methods Of Treating Ulcers And Related Symptoms In Non-human Animalsapplication
—Methods Of Treating Diarrhea In Pre-weaned, Neonatal And Young Non-human Animalsapplication
—Methods Of Treating Porcine Epidemic Diarrheal Virus In Pigletsapplication
—Treatment Of Gastric Ulcers In Non-human Animals Using Nonenterically Coated Or Protected Formulations Comprising Croton- Or Calophyllum-derived Proanthocyanidin Polymers Or Botanical Extractsapplication
—Use Of Croton- Or Calophyllum-derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Nonhuman Animalsapplication
—Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-human Animalsapplication

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.